BC 007

Drug Profile

BC 007

Alternative Names: BC-007

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Berlin Cures
  • Class Nucleotide aptamers; Peptide aptamers; Proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dilated cardiomyopathy
  • Phase Unknown Chronic heart failure

Most Recent Events

  • 04 Nov 2016 Berlin Cures plans a phase II/III trial for Chronic heart failure in Germany (IV)
  • 01 Nov 2016 Investigation in Chronic heart failure in Germany (IV)
  • 28 Sep 2016 Preclinical trials in Dilated cardiomyopathy in Germany (Parenteral) before September 2016 (Berlin cures pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top